Oncology

Phase 1 data support further assessment of DK210 (EGFR) in solid tumors such as renal cell carcinoma and non–small cell lung cancer.

Julie M. Vose, MD, MBA, highlights the push toward gender diversity in medical oncology.

Major clinical trials lack documentation and participation data on Native Hawaiians and Pacific Islanders, a recent study finds.

Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.

STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.

STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.

Findings from 3 studies combining birth and cancer registers showed postponing childbearing partially correlated with cancer increases in pregnant women.

Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.

Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.

Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.

The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.

Adolescents and young adults with cancer more commonly experience financial toxicity and unmet social needs.

Those with pathogenic variants had a higher likelihood of communicating with clinicians and family members about test results.

Review data demonstrated a variation in opioid prescriptions for cancer-related pain between oncology providers and pain management providers.

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Investigators are currently assessing possible predictors for response to inavolisib as part of the phase 2 CRAFT trial.

Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.

Julie M. Vose, MD, MBA, reviews the rising cancer diagnoses that are estimated to impact 2 million people in 2024.

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.

Cancer rehabilitation medicine may help bridge a gap in oncology care, according to Jessica Cheng, MD.

It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.

Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.

Jessica Cheng, MD, noted that working with patients in the field of cancer rehabilitation to improve recovery times brings her joy.

Neil M. Iyengar, MD, highlights how to best integrate exercise oncology into multidisciplinary care.

Further development of vebreltinib in patients with MET fusions is being considered following results from the phase 2 SPARTA trial.

The FDA has set a Prescription Drug User Fee Act date of February 17, 2025, to approve vimseltinib for patients with tenosynovial giant cell tumor.

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Genetic testing may be beneficial post-cancer diagnosis for reducing cancer risk for families with hereditary cancer syndromes and managing treatment.

Results from a retrospective cohort study display evidence of potential benefit from GLP-1RAs for the reduction of 13 obesity-associated cancers for those with type 2 diabetes.